Joseph Harding - Publications

Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.

Journal: Antimicrobial agents and chemotherapy

Published: February 06, 2023

Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.

Journal: The Journal of antimicrobial chemotherapy

Published: November 27, 2021

Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients.

Journal: Antimicrobial agents and chemotherapy

Published: July 26, 2021

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: November 23, 2020

Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.

Journal: Antimicrobial agents and chemotherapy

Published: June 30, 2020

Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: October 20, 2019

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: July 12, 2018

Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: January 04, 2018